Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
Cellular aging process can promote idiopathic pulmonary fibrosis

Cellular aging process can promote idiopathic pulmonary fibrosis

Researchers develop potential stem cell treatment for several lung conditions

Researchers develop potential stem cell treatment for several lung conditions

New survey reveals emotional, practical challenges facing people with idiopathic pulmonary fibrosis

New survey reveals emotional, practical challenges facing people with idiopathic pulmonary fibrosis

Targeting immune cells could lead to new treatments for pulmonary fibrosis

Targeting immune cells could lead to new treatments for pulmonary fibrosis

Study identifies two T cell biomarkers that may predict survival trajectory of IPF patients

Study identifies two T cell biomarkers that may predict survival trajectory of IPF patients

CUMC researchers create new organoids that mimic features of full-sized lung

CUMC researchers create new organoids that mimic features of full-sized lung

Researcher examines scarring process in hope of preventing chronic lung transplant rejection

Researcher examines scarring process in hope of preventing chronic lung transplant rejection

Two thirds of IPF patients report being involved during the decision-making process for the most appropriate treatment

Two thirds of IPF patients report being involved during the decision-making process for the most appropriate treatment

Mayo Clinic study finds link between biology of aging and idiopathic pulmonary fibrosis

Mayo Clinic study finds link between biology of aging and idiopathic pulmonary fibrosis

Pulmospheres could serve as personalized, predictive model for assessing effect of IPF drugs

Pulmospheres could serve as personalized, predictive model for assessing effect of IPF drugs

Increasing idiopathic pulmonary fibrosis research

Increasing idiopathic pulmonary fibrosis research

Nanoparticle exposure can trigger dormant viruses in lung tissue cells

Nanoparticle exposure can trigger dormant viruses in lung tissue cells

IPF diagnosis: how do patients feel about the discussion with their physician?

IPF diagnosis: how do patients feel about the discussion with their physician?

Researchers crack genetic code of lung tissues to identify novel targets for treating IPF

Researchers crack genetic code of lung tissues to identify novel targets for treating IPF

Veracyte announces new data suggesting ability of Afirma GEC in thyroid cancer diagnosis

Veracyte announces new data suggesting ability of Afirma GEC in thyroid cancer diagnosis

New survey shows majority of patients happy with how physicians manage discussion on IPF diagnosis

New survey shows majority of patients happy with how physicians manage discussion on IPF diagnosis

British Lung Foundation announces funding for IPF research

British Lung Foundation announces funding for IPF research

Myeloid-derived suppressor cells may serve as biomarkers for idiopathic pulmonary fibrosis

Myeloid-derived suppressor cells may serve as biomarkers for idiopathic pulmonary fibrosis

Boehringer Ingelheim and Duke expand collaboration to create largest patient registry for idiopathic pulmonary fibrosis (IPF)

Boehringer Ingelheim and Duke expand collaboration to create largest patient registry for idiopathic pulmonary fibrosis (IPF)

VUMC receives $11 million renewal grant to advance pulmonary fibrosis research

VUMC receives $11 million renewal grant to advance pulmonary fibrosis research